Dimerix Ltd (ASX: DXB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Dimerix Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$219.14 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
600.40 million
Earnings per share
-0.027
Dividend per share
N/A
Year To Date Return
-30.00%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Dimerix Ltd (ASX: DXB)
Latest News
Healthcare Shares
Dimerix (ASX:DXB) share price jumps on COVID study update
Healthcare Shares
Dimerix (ASX:DXB) share price soars as boss looks back on 'pivotal' year
Share Gainers
These 3 ASX Healthcare shares have soared over 10% today
Healthcare Shares
Dimerix (ASX:DXB) share price soars 9% on COVID-19 news
Healthcare Shares
The Dimerix (ASX:DXB) share price is up 3% on Thursday
Share Fallers
Dimerix (ASX:DXB) share price down 10% after prospectus issued
Healthcare Shares
Dimerix (ASX:DXB) share price rockets 50% on capital raise and results
Share Gainers
Why the Dimerix (ASX:DXB) share price is rocketing higher
Share Market News
Why the Dimerix (ASX:DXB) share price is up today
Share Market News
Why the Dimerix (ASX:DXB) share price is surging 6% higher today
Share Market News
Why the Dimerix (ASX:DXB) share price has plunged 63% today
Growth Shares
3 ASX shares that could make you rich
1❯
DXB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Dimerix Ltd
A clinical stage drug discovery and development company. The operational headquarters of the company are in Melbourne, where Dimerix's lead clinical program is a Phase 2 study in Chronic Kidney Disease, DMX-200
DXB Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 17 Mar 2026 | $0.39 | $0.04 | 11.43% | 1,438,129 | $0.37 | $0.40 | $0.35 |
| 16 Mar 2026 | $0.35 | $0.00 | 0.00% | 1,471,053 | $0.34 | $0.37 | $0.34 |
| 13 Mar 2026 | $0.35 | $-0.02 | -5.41% | 1,677,729 | $0.36 | $0.36 | $0.35 |
| 12 Mar 2026 | $0.37 | $0.01 | 2.78% | 991,170 | $0.37 | $0.37 | $0.36 |
| 11 Mar 2026 | $0.36 | $-0.02 | -5.33% | 1,213,918 | $0.38 | $0.38 | $0.36 |
| 10 Mar 2026 | $0.38 | $0.00 | 0.00% | 1,400,980 | $0.39 | $0.42 | $0.38 |
| 09 Mar 2026 | $0.38 | $-0.03 | -7.41% | 1,633,277 | $0.40 | $0.40 | $0.37 |
| 06 Mar 2026 | $0.41 | $0.00 | 0.00% | 724,927 | $0.40 | $0.41 | $0.39 |
| 05 Mar 2026 | $0.41 | $0.01 | 2.53% | 651,349 | $0.40 | $0.42 | $0.40 |
| 04 Mar 2026 | $0.40 | $-0.01 | -2.44% | 2,420,988 | $0.41 | $0.41 | $0.38 |
| 03 Mar 2026 | $0.41 | $-0.03 | -6.82% | 2,713,552 | $0.44 | $0.45 | $0.40 |
| 02 Mar 2026 | $0.44 | $-0.03 | -6.32% | 1,162,594 | $0.46 | $0.46 | $0.44 |
| 27 Feb 2026 | $0.48 | $0.02 | 4.40% | 541,773 | $0.46 | $0.48 | $0.46 |
| 26 Feb 2026 | $0.46 | $0.02 | 4.55% | 278,453 | $0.47 | $0.47 | $0.45 |
| 25 Feb 2026 | $0.44 | $-0.01 | -2.25% | 512,148 | $0.45 | $0.46 | $0.44 |
| 24 Feb 2026 | $0.45 | $-0.01 | -2.22% | 641,914 | $0.46 | $0.46 | $0.45 |
| 23 Feb 2026 | $0.45 | $-0.02 | -4.21% | 711,828 | $0.46 | $0.47 | $0.45 |
| 20 Feb 2026 | $0.48 | $0.01 | 2.13% | 697,242 | $0.47 | $0.48 | $0.46 |
| 19 Feb 2026 | $0.47 | $-0.01 | -2.11% | 554,493 | $0.48 | $0.48 | $0.47 |
| 18 Feb 2026 | $0.48 | $-0.01 | -2.08% | 112,602 | $0.48 | $0.49 | $0.47 |
| 17 Feb 2026 | $0.48 | $-0.02 | -4.04% | 1,861,277 | $0.50 | $0.50 | $0.48 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 12 Dec 2025 | Mark Diamond | Issued | 300,000 | $96,300 |
Issue of options. $96,300 (Black-Scholes valuation)
|
| 12 Dec 2025 | Hugh Alsop | Issued | 300,000 | $96,300 |
Issue of options. $96,300 (Black-Scholes valuation)
|
| 12 Dec 2025 | Nina Webster | Issued | 2,500,000 | $1,093,500 |
Issue of options. $1,093,500 (Black-Scholes valuation)
|
| 12 Dec 2025 | Sonia Poli | Issued | 300,000 | $96,300 |
Issue of options. $96,300 (Black-Scholes valuation)
|
| 12 Dec 2025 | Clinton Snow | Issued | 300,000 | $96,300 |
Issue of options. $96,300 (Black-Scholes valuation)
|
| 30 Jun 2025 | Sonia Poli | Expiry | 47 | $27 |
Options expired.
|
| 17 Jun 2025 | Sonia Poli | Buy | 73,788 | $11,363 |
Exercise of options.
|
| 17 Jun 2025 | Sonia Poli | Exercise | 73,788 | $11,363 |
Exercise of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Mark P Diamond | Non-Executive ChairmanNon-Executive Director | Dec 2023 |
Mr Diamond is a senior pharmaceutical executive with thirty years' experience within the pharmaceutical and biotechnology industries. Prior to his time at Antisense, he served in senior product and business development roles at Faulding Pharmaceuticals (now Pfizer) within their US, European and international pharmaceutical operations.
|
| Mr Hugh Alsop | Non-Executive Director | May 2017 |
Mr Alsop is an accomplished and commercially focused executive with experience in international business development, partnering, drug development and leadership of scientific teams. Hugh is currently CEO of Kinoxis Therapeutics, a private company developing novel therapeutics for substance use disorders and other neurological conditions. Prior to Kinoxis, Hugh is also a Non-Executive Director of private companies Hatchtech Pty Ltd, Servatus Ltd and Avalyn Australia Pty Ltd.
|
| Dr Nina Webster | Chief Executive OfficerManaging Director | Aug 2018 |
Dr Webster has experience in the pharmaceutical industry, with leadership roles across strategy, commercialization, intellectual property, scientific and operational aspects of product development. She is also the Non-Executive Chairperson for SYNthesis BioVentures and a Non-Executive Director of Linear Clinical Research Limited.
|
| Dr Sonia Maria Poli | Non-Executive Director | Jul 2015 |
Dr Poli is a R&D professional with 25+ years' international experience in large and small pharmaceutical companies. She is an advisor for several early and late-stage drug development projects. She was formerly Executive Manager at AC Immune, a Nasdaq listed company, and Chief Scientific Officer at Sybilla biotech, Minoryx and Addex Therapeutics and she has previously worked within Swiss Stock Exchange listed company Hoffman la Roche.
|
| Mr Clinton Snow | Non-Executive Director | May 2023 |
Mr Snow is an experienced technology and governance professional with over 20 years in engineering leadership, project delivery, risk management and AI. Additionally, he provides advisory services to a family office with multiple investments in the Australian biotech sector.
|
| Mr Michael (Mike) Tonroe | Chief Financial OfficerCompany Secretary | Jan 2026 |
-
|
| Dr Robert Shepherd | Chief Commercialisation Officer |
-
|
|
| Michael (Mike) Tonroe | Chief Financial OfficerCompany Secretary |
-
|
|
| Dr David Fuller | Chief Medical Officer |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Mr Peter Fletcher Meurs | 40,018,964 | 6.67% |
| Skiptan Pty Ltd <P&M Meurs Family A/C> | 36,865,281 | 6.14% |
| J P Morgan Nominees Australia Pty Limited | 17,873,170 | 2.98% |
| Citicorp Nominees Pty Limited | 14,807,737 | 2.47% |
| HSBC Custody Nominees (Australia) Limited | 13,084,110 | 2.18% |
| Precision Opportunities Fund Ltd <Investment A/C> | 11,000,000 | 1.83% |
| National Nominees Limited | 8,325,533 | 1.39% |
| BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 7,014,440 | 1.17% |
| Mr Richard Stanley De Ravin | 6,526,668 | 1.09% |
| Skiptan Pty Ltd <P&M Meurs Family A/C> i | 5,928,514 | 0.99% |
| Bavaria Bay Pty Ltd | 5,765,000 | 0.96% |
| Yodambao Pty Ltd <Yodambao Investment A/C> | 5,480,732 | 0.91% |
| Mrs Melinda Jane Coates & Mr Andrew Joseph Coates <Melindajcoates Superfund A/C> | 5,450,000 | 0.91% |
| Mr Philip Robert Scott | 5,050,000 | 0.84% |
| Mrs Julie Maree Scott | 5,050,000 | 0.84% |
| Mr Peter Fletcher Meurs i | 4,446,552 | 0.74% |
| BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 4,332,453 | 0.72% |
| Mr Andrew Joseph Coates & Mrs Melinda Jane Coates <Aj & Mj Coates S/F A/C> | 4,300,000 | 0.72% |
| Mr David William Pearson & Mrs Susan Dawn Pearson <Pearson Super Fund A/C> | 3,750,493 | 0.61% |
| Mrs Gwen Murray Pfleger <Pfleger Family A/C> | 3,650,379 | 0.61% |
| UBS Nominees Pty Ltd | 3,585,070 | 0.60% |